Glycan Recognition by Human Blood Mononuclear Cells with an Emphasis on Dendritic Cells
Overview
Endocrinology
Authors
Affiliations
Dendritic cells (DCs) play crucial roles in innate and adaptive immune response, for which reason targeting antigen to these cells is an important strategy for improvement of vaccine development. To this end, we explored recognition of DCs lectins by glycans. For selection of the glycan "vector", a library of 229 fluorescent glycoprobes was employed to assess interaction with the CD14CD16CD83 blood mononuclear cell population containing the DCs known for their importance in antigen presentation to T-lymphocytes. It was found that: 1) the glycan-binding profiles of this CD14CD16CD83 subpopulation were similar but not identical to DCs of monocyte origin (moDCs); 2) the highest percentage of probe-positive cells in this CD14 CD16CD83 subpopulation was observed for GalNAcα1-2Galβ (A), (Neu5Acα) and three mannose-reach glycans; 3) subpopulation of CD14CD16 cells preferentially bound 4'-O-Su-LacdiNAc. Considering the published data on specificity of DCs binding, the glycans showing particular selectivity for the CD14 CD16CD83 cells are likely interacting with macrophage galactose binding lectin (MGL), siglec-7 and dectin-2. In contrast, DC-SIGN is not apparently involved, even in case of mannose-rich glycans. Taking into consideration potential in vivo competition between glycan "vectors" and glycans within glycocalyx, attempting to target vaccine to DCs glycan-binding receptors should focus on A and (Neu5Acα) as the most promising vectors.
Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance.
Castenmiller C, Keumatio-Doungtsop B, van Ree R, de Jong E, van Kooyk Y Front Immunol. 2021; 12:643240.
PMID: 33679806 PMC: 7933040. DOI: 10.3389/fimmu.2021.643240.
40 years of glyco-polyacrylamide in glycobiology.
Tuzikov A, Chinarev A, Shilova N, Gordeeva E, Galanina O, Ovchinnikova T Glycoconj J. 2021; 38(1):89-100.
PMID: 33443721 DOI: 10.1007/s10719-020-09965-5.
Glycan-binding profile of DC-like cells.
Rapoport E, Moiseeva E, Aronov D, Khaidukov S, Pazynina G, Tsygankova S Glycoconj J. 2019; 37(1):129-138.
PMID: 31834559 DOI: 10.1007/s10719-019-09897-9.
An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides.
Eggink L, Roby K, Cote R, Hoober J J Immunother Cancer. 2018; 6(1):28.
PMID: 29665849 PMC: 5905120. DOI: 10.1186/s40425-018-0339-5.